Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $283,813.76 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 2,752 shares of the firm’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $103.13, for a total transaction of $283,813.76. Following the sale, the insider now owns 16,944 shares in the company, valued at approximately $1,747,434.72. This trade represents a 13.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Ariel Hurley also recently made the following trade(s):

• On Monday, March 3rd, Ariel Hurley sold 3,203 shares of Blueprint Medicines stock. The shares were sold at an average price of $92.62, for a total value of $296,661.86.

Blueprint Medicines Stock Performance

NASDAQ:BPMC opened at $97.74 on Friday. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The firm’s fifty day simple moving average is $88.49 and its 200 day simple moving average is $93.74. The stock has a market cap of $6.31 billion, a P/E ratio of -90.50 and a beta of 0.83. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company had revenue of $149.41 million for the quarter, compared to analysts’ expectations of $158.31 million. During the same quarter in the prior year, the firm earned $1.40 EPS. Blueprint Medicines’s quarterly revenue was up 55.5% compared to the same quarter last year. As a group, research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BPMC. Avoro Capital Advisors LLC bought a new position in Blueprint Medicines in the fourth quarter worth $103,356,000. Norges Bank bought a new position in shares of Blueprint Medicines in the 4th quarter worth about $62,028,000. Jennison Associates LLC bought a new stake in Blueprint Medicines during the fourth quarter worth about $31,417,000. Rock Springs Capital Management LP grew its holdings in Blueprint Medicines by 42.7% in the fourth quarter. Rock Springs Capital Management LP now owns 1,096,899 shares of the biotechnology company’s stock worth $95,672,000 after purchasing an additional 328,123 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Blueprint Medicines by 8.0% during the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company’s stock valued at $373,421,000 after purchasing an additional 316,754 shares in the last quarter.

Analyst Ratings Changes

BPMC has been the topic of several recent research reports. Wolfe Research initiated coverage on Blueprint Medicines in a report on Tuesday, March 18th. They set an “outperform” rating on the stock. Wedbush restated an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in a report on Thursday, May 1st. JPMorgan Chase & Co. increased their target price on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Jefferies Financial Group initiated coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They issued a “buy” rating and a $135.00 price target for the company. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $126.56.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.